---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099404"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:51:12.833824+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026

## Summary
- Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
- Preliminary cash and cash equivalents ~$535M as of Feb 28, 2026, including ~$316M from Feb 2026 public offering.
- DMR-001 (anti-mutCALR antibody) IND/CTA on track for mid-2026; proof-of-concept data expected mid-2027.
- DMR-002 IND/CTA planned for H2 2026; DMR-003 IND/CTA in 2027.
- Acquisition of privately held Damora closed Nov 2025 with ~$285M private investment.

## SEC filing metadata
- accession: 0001193125-26-099404
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526099404/0001193125-26-099404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526099404/dmra-20260306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099404
- JSON: https://secwatch.observer/filing/0001193125-26-099404.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099404.txt

## Source-grounded claims
- claim_id: d4b1a745a394b7881437a3a2603933cd880178c1
  claim: Damora Therapeutics, Inc.: Amended certificate of incorporation to change company name from Galecto, Inc. to Damora Therapeutics, Inc (effective 2026-03-10).
  evidence_excerpt: On March 6, 2026, the Company filed with the Secretary of State of the State of Delaware an amendment to its Amended and Restated Certificate of Incorporation to change the name of the Company from "Galecto, Inc." to "Damora Therapeutics, Inc." (the "Name Change Amendment"). The Name Change Amendment became effective at 12:01 a.m. Eastern Time on March 10, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312526099404/0001193125-26-099404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.